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Background
The lack of clinical data for orphan drugs and the develop-
ment of “precision medicines” or advanced therapies have
required a new regulatory approach to guarantee a mar-
keting authorization for new and innovative medicines.
What is actually changing in the scenario is the way
Agencies are managing the regulatory procedures to
ensure a rapid access to treatment for patients with
unmet medical needs.
In the last few years EMA and National Agencies have
provided a lot of scientific advices (SA) to companies
and applicants about orphan designation, CTs design,
marketing authorisation procedures and HTA
evaluations.
Currently the global scenario is already changing as we
are issuing licenses for marketing authorization under
exceptional circumstances and conditional marketing
authorizations. The legislative framework is also changing
with the new Pharmacovigilance Directive and the new
Regulation on Clinical Trials entering into force progres-
sively by 2015.
Materials and methods
The new Pharmacovigilance Legislation supports a
Progressive Patient Access Scheme (PPAS, or “Adap-
tive Licensing”) approach by expanding EMA authority
to request mandatorily to Applicants a post-marketing
evaluation of effectiveness in addition to safety.
The basic principles of PPAS approaches are facilitat-
ing early access to an early medicine approval, by
acknowledging and managing uncertainty about favour-
able and unfavourable effects. The result will be
achieved through the conduction of optimised RCTs,
the monitoring of risk-based SA and the harmonisation
of RCTs platforms.
Lots of effort is needed by everyone through a new
level of cooperation, in particular regulators, companies
and the CROs need to go down to patient level in order
to evaluate how the trial is proceeding and by avoiding
complex policies.
Moreover, patients have to accept a certain level of
uncertainty as the clinical studies are not completed and
Clinical Trials investigators need a continuous talking to
patients during the drug development to ensure the
higher level of achievable safety.
Results and conclusions
A successful PPAS pathway depends on the willingness of
patients, regulators, health-care providers and payers to
accept a greater level of uncertainty using the new medi-
cine in the expectation of an improved benefit risk profile.
Furthermore, PPAS approach could facilitate a more
open and timely strong scientific dialogue and signifi-
cant cooperation among stakeholders and a time reduc-
tion to full market approval resulting into a possible
impact reduction on the overall cost of development.
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